Skip to Content

Generic Technivie Availability

Technivie is a brand name of ombitasvir/paritaprevir/ritonavir, approved by the FDA in the following formulation(s):

TECHNIVIE (ombitasvir; paritaprevir; ritonavir - tablet;oral)

  • Manufacturer: ABBVIE INC
    Approval date: July 24, 2015
    Strength(s): 12.5MG;75MG;50MG [RLD]

Has a generic version of Technivie been approved?

No. There is currently no therapeutically equivalent version of Technivie available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Technivie. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for improving pharmacokinetics
    Patent 6,037,157
    Issued: March 14, 2000
    Inventor(s): Norbeck; Daniel W. & Kempf; Dale J. & Leonard; John M. & Bertz; Richard J.
    Assignee(s): Abbott Laboratories
    A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Patent expiration dates:
    • June 26, 2016
      ✓ 
      Patent use: USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
    • December 26, 2016
      ✓ 
      Pediatric exclusivity
  • Method for improving pharmacokinetics
    Patent 6,703,403
    Issued: March 9, 2004
    Inventor(s): Daniel W.; Norbeck & Dale J.; Kempf & John M.; Leonard & Richard J.; Bertz
    Assignee(s): Abbott Laboratories
    A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Patent expiration dates:
    • June 26, 2016
      ✓ 
      Patent use: USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
    • December 26, 2016
      ✓ 
      Pediatric exclusivity
  • Polymorph of a pharmaceutical
    Patent 7,148,359
    Issued: December 12, 2006
    Inventor(s): Chemburkar; Sanjay R. & Patel; Ketan
    Assignee(s): Abbott Laboratories
    A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
    Patent expiration dates:
    • July 19, 2019
      ✓ 
      Drug product
    • January 19, 2020
      ✓ 
      Pediatric exclusivity
  • Solid dispersion pharamaceutical formulations
    Patent 7,364,752
    Issued: April 29, 2008
    Inventor(s): Fort; James J. & Krill; Steven L. & Law; Devalina & Qiu; Yihong & Porter; William R. & Schmitt; Eric A.
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.
    Patent expiration dates:
    • November 10, 2020
      ✓ 
      Drug product
    • May 10, 2021
      ✓ 
      Pediatric exclusivity
  • Solid pharmaceutical dosage form
    Patent 8,268,349
    Issued: September 18, 2012
    Inventor(s): Rosenberg; Joerg & Reinhold; Ulrich & Liepold; Bernd & Berndl; Gunther & Breitenbach; Joerg & Alani; Laman & Ghosh; Soumojeet
    Assignee(s): Abbott Laboratories
    A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Patent expiration dates:
    • August 25, 2024
      ✓ 
      Drug product
    • February 25, 2025
      ✓ 
      Pediatric exclusivity
  • Solid pharmaceutical dosage form
    Patent 8,399,015
    Issued: March 19, 2013
    Assignee(s): AbbVie Inc.
    A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
    Patent expiration dates:
    • August 25, 2024
      ✓ 
      Drug product
    • February 25, 2025
      ✓ 
      Pediatric exclusivity
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent 8,420,596
    Issued: April 16, 2013
    Assignee(s): Abbott Laboratories Enanta Pharmaceuticals, Inc.
    The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Patent expiration dates:
    • April 10, 2031
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • October 10, 2031
      ✓ 
      Pediatric exclusivity
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent 8,642,538
    Issued: February 4, 2014
    Assignee(s): AbbVie, Inc.
    The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Patent expiration dates:
    • September 10, 2029
      ✓ 
      Patent use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Solid compositions
    Patent 8,686,026
    Issued: April 1, 2014
    Assignee(s): AbbVie Inc.
    The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
    Patent expiration dates:
    • June 9, 2031
      ✓ 
      Drug product
  • Anti-viral compounds
    Patent 8,691,938
    Issued: April 8, 2014
    Assignee(s): AbbVie Inc.
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Patent expiration dates:
    • April 13, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Anti-viral compounds
    Patent 9,006,387
    Issued: April 14, 2015
    Assignee(s): AbbVie Inc.
    Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Patent expiration dates:
    • June 10, 2030
      ✓ 
      Patent use: TREATMENT OF HCV INFECTION USING OMBITASVIR
  • Compositions and methods for treating HCV
    Patent 9,044,480
    Issued: June 2, 2015
    Assignee(s): AbbVie Inc.
    The present invention features methods of using Compound I to suppress HCV mutants, treat treatment-experienced HCV patients, and treat HCV patients having non-CC IL28B rs12979860 genotype.
    Patent expiration dates:
    • April 10, 2031
      ✓ 
      Patent use: TREATMENT OF HCV INFECTION USING PARITAPREVIR

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 24, 2018 - NEW PRODUCT
    • December 19, 2019 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide